262 related articles for article (PubMed ID: 20001317)
1. Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection.
Lee DY; Lin X; Paskaleva EE; Liu Y; Puttamadappa SS; Thornber C; Drake JR; Habulin M; Shekhtman A; Canki M
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1231-41. PubMed ID: 20001317
[TBL] [Abstract][Full Text] [Related]
2. Sargassum fusiforme fraction is a potent and specific inhibitor of HIV-1 fusion and reverse transcriptase.
Paskaleva EE; Lin X; Duus K; McSharry JJ; Veille JC; Thornber C; Liu Y; Lee DY; Canki M
Virol J; 2008 Jan; 5():8. PubMed ID: 18197976
[TBL] [Abstract][Full Text] [Related]
3. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
4. P2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection.
Swartz TH; Esposito AM; Durham ND; Hartmann BM; Chen BK
J Virol; 2014 Oct; 88(19):11504-15. PubMed ID: 25031337
[TBL] [Abstract][Full Text] [Related]
5. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.
Surdo M; Balestra E; Saccomandi P; Di Santo F; Montano M; Di Carlo D; Sarmati L; Aquaro S; Andreoni M; Svicher V; Perno CF; Ceccherini-Silberstein F
PLoS One; 2013; 8(7):e68076. PubMed ID: 23874501
[TBL] [Abstract][Full Text] [Related]
7. Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.
Ayouba A; Cannou C; Nugeyre MT; Barré-Sinoussi F; Menu E
Retrovirology; 2008 Mar; 5():31. PubMed ID: 18377645
[TBL] [Abstract][Full Text] [Related]
8. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
[TBL] [Abstract][Full Text] [Related]
9. CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability.
Ji C; Kopetzki E; Jekle A; Stubenrauch KG; Liu X; Zhang J; Rao E; Schlothauer T; Fischer S; Cammack N; Heilek G; Ries S; Sankuratri S
J Biol Chem; 2009 Feb; 284(8):5175-85. PubMed ID: 19097993
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells.
Popik W; Alce TM; Au WC
J Virol; 2002 May; 76(10):4709-22. PubMed ID: 11967288
[TBL] [Abstract][Full Text] [Related]
11. Palmitic acid analogs exhibit nanomolar binding affinity for the HIV-1 CD4 receptor and nanomolar inhibition of gp120-to-CD4 fusion.
Paskaleva EE; Xue J; Lee DY; Shekhtman A; Canki M
PLoS One; 2010 Aug; 5(8):e12168. PubMed ID: 20730055
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
Bosch B; Blanco J; Pauls E; Clotet-Codina I; Armand-Ugón M; Grigorov B; Muriaux D; Clotet B; Darlix JL; Esté JA
Antimicrob Agents Chemother; 2005 Oct; 49(10):4296-304. PubMed ID: 16189111
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4+ cell proliferation and activation.
Locher CP; Witt SA; Kassel R; Dowell NL; Fujimura S; Levy JA
J Gen Virol; 2005 Apr; 86(Pt 4):1171-1179. PubMed ID: 15784911
[TBL] [Abstract][Full Text] [Related]
15. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.
Ghaffari G; Tuttle DL; Briggs D; Burkhardt BR; Bhatt D; Andiman WA; Sleasman JW; Goodenow MM
J Virol; 2005 Nov; 79(21):13250-61. PubMed ID: 16227248
[TBL] [Abstract][Full Text] [Related]
16. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
Blanco J; Barretina J; Clotet B; Esté JA
J Leukoc Biol; 2004 Oct; 76(4):804-11. PubMed ID: 15258189
[TBL] [Abstract][Full Text] [Related]
17. Envelope-dependent restriction of human immunodeficiency virus type 1 spreading in CD4(+) T lymphocytes: R5 but not X4 viruses replicate in the absence of T-cell receptor restimulation.
Vicenzi E; Bordignon PP; Biswas P; Brambilla A; Bovolenta C; Cota M; Sinigaglia F; Poli G
J Virol; 1999 Sep; 73(9):7515-23. PubMed ID: 10438841
[TBL] [Abstract][Full Text] [Related]
18. Recombinant extracellular domains of tetraspanin proteins are potent inhibitors of the infection of macrophages by human immunodeficiency virus type 1.
Ho SH; Martin F; Higginbottom A; Partridge LJ; Parthasarathy V; Moseley GW; Lopez P; Cheng-Mayer C; Monk PN
J Virol; 2006 Jul; 80(13):6487-96. PubMed ID: 16775336
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CD3/CD28-mediated activation of the MEK/ERK signaling pathway represses replication of X4 but not R5 human immunodeficiency virus type 1 in peripheral blood CD4(+) T lymphocytes.
Popik W; Pitha PM
J Virol; 2000 Mar; 74(6):2558-66. PubMed ID: 10684270
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a post-entry barrier to R5 HIV-1 infection of CD4 memory T cells.
Vyakarnam A; Eyeson J; Teo I; Zuckerman M; Babaahmady K; Schuitemaker H; Shaunak S; Rostron T; Rowland-Jones S; Simmons G; Clapham P
AIDS; 2001 Sep; 15(13):1613-26. PubMed ID: 11546935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
